Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has increased by 4.75 compared to its previous closing price of 7.37. However, the company has seen a -5.16% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-04-10 that SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?
The stock has a 36-month beta value of 0.08. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRVI is 106.83M, and at present, short sellers hold a 4.79% of that float. On April 24, 2024, the average trading volume of MRVI was 2.77M shares.
MRVI’s Market Performance
The stock of Maravai LifeSciences Holdings Inc (MRVI) has seen a -5.16% decrease in the past week, with a -11.87% drop in the past month, and a 22.54% gain in the past quarter. The volatility ratio for the week is 6.34%, and the volatility levels for the past 30 days are at 5.45% for MRVI. The simple moving average for the past 20 days is -6.14% for MRVI’s stock, with a -3.81% simple moving average for the past 200 days.
Analysts’ Opinion of MRVI
Many brokerage firms have already submitted their reports for MRVI stocks, with Craig Hallum repeating the rating for MRVI by listing it as a “Buy.” The predicted price for MRVI in the upcoming period, according to Craig Hallum is $15 based on the research report published on April 10, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see MRVI reach a price target of $8, previously predicting the price at $10. The rating they have provided for MRVI stocks is “Buy” according to the report published on December 12th, 2023.
MRVI Trading at 2.49% from the 50-Day Moving Average
After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.55% of loss for the given period.
Volatility was left at 5.45%, however, over the last 30 days, the volatility rate increased by 6.34%, as shares sank -9.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.86% upper at present.
During the last 5 trading sessions, MRVI fell by -5.16%, which changed the moving average for the period of 200-days by -36.62% in comparison to the 20-day moving average, which settled at $8.19. In addition, Maravai LifeSciences Holdings Inc saw 17.86% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for MRVI
Current profitability levels for the company are sitting at:
- -0.1 for the present operating margin
- 0.48 for the gross margin
The net margin for Maravai LifeSciences Holdings Inc stands at -0.42. The total capital return value is set at -0.02. Equity return is now at value -24.75, with -6.31 for asset returns.
Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 1.28. The interest coverage ratio of the stock is -0.63.
Currently, EBITDA for the company is 44.58 million with net debt to EBITDA at 4.71. When we switch over and look at the enterprise to sales, we see a ratio of 3.66. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.
Conclusion
To sum up, Maravai LifeSciences Holdings Inc (MRVI) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
